# Study Design and Description

## Study Design

Describe the study designated

Example:

XXX-123 is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with `r gls('drug')` in adult subjects with disease XYZ. Approximately NNN subjects will be dosed, with the expectation to achieve follow-up of 300 subjects for 6 months and 100 subjects for 1 year.

Patients are designated to three cohorts:

-   Low Dose: Description
-   Dose Switching: Description
-   High Dose: Description

Dosing schedule

Followup schedule
